Inactive Instrument

News Qiagen NV Deutsche Boerse AG

Equities

End-of-day quote Deutsche Boerse AG Other stock markets
- ^EUR	-

11:57am	Wolfe Research Upgrades Qiagen to Outperform From Peer Perform, Price Target is $50	MT
06-21	Qiagen Seeks M&A	CI

Qiagen N : AGM 2024 Voting Results	12:25pm	PU
Wolfe Research Upgrades Qiagen to Outperform From Peer Perform, Price Target is $50	10:57am	MT
Qiagen Seeks M&A	06-21	CI
Transcript : Qiagen N.V. - Shareholder/Analyst Call	06-21
Qiagen N : Stifel – European Healthcare Summit Capital Markets Day Presentation	06-20	PU
Qiagen N : Stifel – European Healthcare Summit Infographic	06-20	PU
Sartorius on the downswing again - low since 2020 is approaching	06-19	DP
Invest Securities Raises Qiagen PT, Maintains Neutral Rating	06-19	MT
UBS Raises Qiagen Price Target to $46 From $44, Maintains Neutral Rating	06-18	MT
JPMorgan Raises Price Target on Qiagen to $54 From $52, Maintains Overweight Rating	06-18	MT
QIAGEN NV : Gets a Neutral rating from UBS	06-18	ZD
QIAGEN NV : Deutsche Bank reaffirms its Buy rating	06-18	ZD
QIAGEN NV : Berenberg remains its Buy rating	06-18	ZD
Frankfurt shares close: Dax recovers	06-17	DP
Transcript : Qiagen N.V. - Analyst/Investor Day	06-17
Dpa-AFX Overview: COMPANIES from 17.06.2024 - 15:15	06-17	DP
Qiagen Targets 7% Annual Sales Growth Through 2028	06-17	MT
Qiagen eyes sales growth of 7% per year until 2028	06-17	RE
QIAGEN announces 2028 strategy for solid profitable growth	06-17	AQ
QIAGEN’s software QCI Interpret accelerates clinical reporting turnaround time for high throughput NGS testing labs	06-13	AQ

No results for this search

QIAGEN : A decent start to 2024; guidance unchanged

April 30, 2024 at 02:32 pm